Lallemand Pharma offers to its network of pharmaceutical partners PMBL® sublingual tablets, made of unique active substance of bacterial lysate obtained by mechanical lysis. Our PMBL® based drugs are indicated in the prevention of respiratory infections. Our drugs improve patients life thanks to a reinforced immune system: less respiratory infections and less exacerbations lead to better breathing and well-being!
The efficacy of our drug has been documented in many randomized clinical studies and remains our focus for further clinical research, in areas such as Chronic Obstructive Pulmonary Disease (COPD) or asthma.
PMBL®sublingual tablets are successfully marketed in more than twenty five countries worldwide, under different brand names : Ismigen®, Immubron®, Respibron®, PIR-05® and Pulmigen®, thanks to our global network of pharmaceutical partners.